Abstract
This paper describes the immunomodulatory and therapeutic properties of the alkyl lysophospholipids [ALP; 1-O-octadecyl-2-O-rac-glycero-3-phosphocholine (ET-18-OCH3)]. ALP was able to activate macrophages both in vitro and in vivo as well as to act as an immunoadjuvant for syngeneic tumor vaccines. However, ALP appeared to be transferred, at least in part, to the macrophage membrane, and some of the tumoricidal macrophage-activating properties seem to be associated with the direct cytotoxic effect of membrane-released ALP. ALP also had some therapeutic activity for experimental and spontaneous metastases, requiring administration three but not two times weekly at near-toxic doses; this suggests that at least some of its therapeutic activity is due to direct cytotoxicity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- ALP:
-
alkyl lysophospholipids
- BRM:
-
biological response modifiers
- poly (I,C)-LC:
-
polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose
- MLR:
-
mixed lymphocyte reaction
- MLTR-CMC:
-
mixed lymphocyte tumor response-cell-mediated cytotoxicity
- HBSS:
-
Hanks’ balanced salts solution
- NK:
-
natural killer
- MTD:
-
maximum tolerated dose
References
Munder, P.G., Ferber, E., Modolell, M., and Fischer, H. (1969)Int. Arch. Allergy 36, 117–128.
Munder, P.G., and Modolell, M. (1974)Recent Results Cancer Res. 47, 244–250.
Munder, P.G., Modelell, M., Ferber, E., and Fischer, H. (1966)Biochemistry Z. 344, 310–313.
Munder, P.G., Modolell, M., and Fischer, H. (1970) inMononuclear Phagocytes (Van Furth, R., ed.) p. 445, Blackwell, Oxford.
Munder, P.G., Weltzien, H.U., and Modolell, M. (1976) inVIIth International Symposium on Immunopathology (Miescher, P.A., ed.) pp. 411–427, Schwabe, Basel, Switzerland.
Munder, P.G., and Modolell, M. (1973)Int. Arch. Allergy 45, 133–135.
Munder, P.G., Modelell, M., Raetz, W., and Luckenbach, G.A. (1973)Eur. J. Immunol. 3, 454–457.
Arnold, B., Reuther, R., and Weltzien, H.U. (1978)Biochim. Biophys. Acta 530, 47–55.
Munder, P.G., Modolell, M., Bausert, W., Oettgen, H.F., and Westphal, O. (1981) inAugmenting Agents in Cancer Therapy (Hersh, E.M., Chirigos, M.A., and Mastrangelo, M.J., eds.) pp. 441–458, Raven Press, New York.
Berdel, W.E., Bausert, W.R., Weltzien, H.U., Modolell, M.L., Widmann, K.H., and Munder, P.G. (1980)Eur. J. Cancer 16, 1199–1204.
Berger, M.R., Munder, P.G., Schmahl, D., and Westphal, O. (1984)Oncology 31, 109–113.
Bertermann, O., and Andreesen, R. (1983) inProceedings of the 13th International Congress on Chemotherapy (Spitzy, K.H., and Karrer, K., eds.) Abstracts SE 12.4.7 A, Part 257, pp. 2–5, Vienna, Austria.
Andreesen, R., Modolell, M., Weltzien, H.U., Eibl, H., Common, H.H., Loehr, G.W., and Munder, P.G. (1978)Cancer Res. 38, 3894–3899.
Long, R.C., Small, W.C., Brynes, R.K., Tidwell, T., Goldstein, J.H., and Vogler, W.R. (1983)Cancer Res. 43, 770–775.
Tidwell, T., Guzman, G., and Vogler, W.R. (1981)Blood 57, 794–797.
Berdel, W.E., Fink, U., Egger, B., Reichert, A., Munder, P.G., and Rastetter, J., (1981)J. Natl. Cancer Inst. 66, 813–817.
Runge, M., Andreesen, R., Pfleiderer, E., and Munder, P.G. (1980)J. Natl. Cancer. Inst. 64, 1301–1306.
Honma, Y., Kasukabe, T., Hozumi, M., Tsushima, S., and Nomura, T. (1981)Cancer Res. 41, 3211–3216.
Storme, G.A., Berdel, W.E., Van Blitterswijk, W.J., Bruyneel, E.A., De Bruyne, G.K., and Mareel, M. (1985)Cancer Res. 45, 351–357.
Talmadge, J.E., Fidler, I.J., and Oldham, R.K. (1985) inScreening for Biological Response Modifiers: Methods and Rationale, pp. 1–193, Martinus Nijhoff, The Hague.
Talmadge, J.E., and Herberman, R.B. (1986)Cancer Treat. Rep. 30, 171–182.
Kripke, M.L. (1977)Cancer Res. 37, 1395–1400.
Kripke, M.L., Gruys, E., and Fidler, I.J. (1978)Cancer Res. 38, 2962–2967.
Dunn, T.B., and Patter, M.J. (1957)J. Natl. Cancer. Inst. 18, 587–601.
Klein, E., and Klein, G. (1964)J. Natl. Cancer Inst. 32, 547–568.
Hart, I.R. (1979)Am. J. Pathol. 97, 587–600.
Click, R.E., Benck, L., and Alter, B.J. (1972)Cell. Immunol. 3, 264–276.
Talmadge, J.E., Benedict, K.L., Uithoven, K.A., and Lenz, B.F. (1984)Immunopharmacology 7, 17–26.
Berdel, W.E., Bausert, W.R.E., Fink, U., Rastetter, J., and Munder, P.G. (1981)Anticancer Res. 1, 345–352.
Berdel, W.E., Greiner, E., Fink, U., Zanker, K.S., Stavrou, D., Trappe, A., Fahlbusch, R., Reichert, A., and Rastetter, J. (1984)Oncology 41, 140–145.
Roos, G., and Berdel, W.E. (1986)Leukemia Res. 10, 195–202.
Berdel, W.E., Van Hoff, D.D., Unger, C., Schick, H.D., Fink, U., Reichert, A., Eibl, H., and Rastetter, J. (1986)Lipids 21, 301–304.
Andreesen, R., Osterhoz, J., Luckenbach, G.A., Costabel, U., Schulz, A., Speth, V., Munder, P.G., and Loehr, G.W. (1984)J. Natl. Cancer Inst. 72, 53–59.
Pfleger, R.C., Piantadosi, C., and Snyder, F. (1967)Biochim. Biophys. Acta 144, 633–648.
Snyder, F., and Wood, R. (1968)Cancer Res. 28, 972–978.
Sykle, R.L., and Snyder, F. (1976) inThe Enzymes of Biological Membranes (Martonosi, A., ed.) Vol. 2, pp. 87–117, Plenum Press, New York.
Herrmann, D.B.J., Ferber, E., and Munder, P.G. (1986)Biochim. Biophys. Acta 876, 28–35.
Author information
Authors and Affiliations
About this article
Cite this article
Talmadge, J.E., Schneider, M., Lenz, B. et al. Immunomodulatory and therapeutic properties of alkyl lysophospholipids in mice. Lipids 22, 871–877 (1987). https://doi.org/10.1007/BF02535547
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02535547